

**Remarks**

After entry of the above amendment, claims 1-32 and 48 will be pending in this application.

Claims 1 to 23 and 26 to 28 are original claims.

Claims 24, 25, and 29 to 32 have been amended.

Claims 33-47 have been cancelled without prejudice.

New Claim 48 has been added without introducing new matter. Support for this new claim can be found for example on page 32, lines 9 to 15 and throughout the application.


Claims 24, 25, and 29 to 32 have been amended merely to remove multiple dependencies.

The specification has been amended to add the "Cross Reference to related application" section showing that this application is claiming priority to an earlier US provisional application.

It is respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: April 20, 2006

  
Lyle W. Spruce, Ph.D.  
Registration No. 53,631

Arena Pharmaceuticals, Inc.  
6166 Nancy Ridge Drive  
San Diego, CA 92121  
Telephone: (858) 453-7200 x1425  
Facsimile: (858) 677-0065